233 related articles for article (PubMed ID: 12586808)
21. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
22. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
[TBL] [Abstract][Full Text] [Related]
23. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience.
Mohanty NK; Nayak RL; Vasudeva P; Arora RP
Urol Oncol; 2008; 26(6):616-9. PubMed ID: 18367121
[TBL] [Abstract][Full Text] [Related]
24. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
Beardo Villar P; Gamaza Martínez R; Gavira Moreno R
Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
[TBL] [Abstract][Full Text] [Related]
26. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.
Gunelli R; Bercovich E; Nanni O; Ballardini M; Frassineti GL; Giovannini N; Fiori M; Pasquini E; Ulivi P; Pappagallo GL; Silvestrini R; Zoli W
Br J Cancer; 2007 Dec; 97(11):1499-504. PubMed ID: 17987035
[TBL] [Abstract][Full Text] [Related]
27. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
28. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
De Santis M; Bachner M; Cerveny M; Kametriser G; Steininger T; Königsberg R; Schratter-Sehn A; Sedlmayer F; Dittrich C
Ann Oncol; 2014 Sep; 25(9):1789-1794. PubMed ID: 24936582
[TBL] [Abstract][Full Text] [Related]
29. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs.
Cozzi PJ; Bajorin DF; Tong W; Nguyen H; Scott J; Heston WD; Dalbagni G
Clin Cancer Res; 1999 Sep; 5(9):2629-37. PubMed ID: 10499642
[TBL] [Abstract][Full Text] [Related]
30. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial.
Oh KS; Soto DE; Smith DC; Montie JE; Lee CT; Sandler HM
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):511-7. PubMed ID: 18977098
[TBL] [Abstract][Full Text] [Related]
31. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).
Gontero P; Casetta G; Maso G; Sogni F; Pretti G; Zitella A; Frea B; Tizzani A
Eur Urol; 2004 Sep; 46(3):339-43. PubMed ID: 15306105
[TBL] [Abstract][Full Text] [Related]
32. Evidence of a clinically significant interaction between warfarin and intravesical gemcitabine.
Kurtzhalts K; Gee ME; Feuz L; Krajewski KC
Am J Health Syst Pharm; 2016 Oct; 73(19):1508-11. PubMed ID: 27646812
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
Uchio EM; Linehan WM; Figg WD; Walther MM
J Urol; 2003 Jan; 169(1):357-60. PubMed ID: 12478189
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
Caffo O; Fellin G; Graffer U; Valduga F; Bolner A; Luciani L; Tomio L; Galligioni E
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1310-6. PubMed ID: 14630267
[TBL] [Abstract][Full Text] [Related]
35. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
Herman JM; Smith DC; Montie J; Hayman JA; Sullivan MA; Kent E; Griffith KA; Esper P; Sandler HM
Urology; 2004 Jul; 64(1):69-73. PubMed ID: 15245938
[TBL] [Abstract][Full Text] [Related]
36. The effects of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin in superficial bladder cancer: a preliminary study.
Cho DY; Bae JH; Moon DG; Cheon J; Lee JG; Kim JJ; Yoon DK; Park HS
J Int Med Res; 2009; 37(6):1823-30. PubMed ID: 20146880
[TBL] [Abstract][Full Text] [Related]
37. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
[TBL] [Abstract][Full Text] [Related]
38. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
Masumori N; Kunishima Y; Hirobe M; Takeuchi M; Takayanagi A; Tsukamoto T; Itoh T
Jpn J Clin Oncol; 2008 Mar; 38(3):182-5. PubMed ID: 18270381
[TBL] [Abstract][Full Text] [Related]
39. Actual experience and future development of gemcitabine in superficial bladder cancer.
Gontero P; Frea B
Ann Oncol; 2006 May; 17 Suppl 5():v123-8. PubMed ID: 16807439
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
